Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. NeuroXPF
WARNING LETTER
•NeuroXPF•March 27, 2020

NeuroXPF – FDA Warning Letter, Mar 27, 2020

Record Details

On March 31, 2020, the FDA and FTC issued a Warning Letter to NeuroXPF regarding the sale of unapproved and misbranded CBD products claiming to mitigate, prevent, treat, diagnose, or cure COVID-19. The agencies reviewed NeuroXPF's websites (neuroxpf.com, facebook.com/NeuroXPF/, twitter.com/NeuroXPF) on March 23 and 27, 2020.

The FDA determined these CBD products are unapproved new drugs, violating section 505(a) of the FD&C Act, and misbranded drugs under section 502. The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d). The letter emphasizes the public health emergency declared for COVID-19.

NeuroXPF is required to immediately cease selling these unapproved products. Within 48 hours, the company must email COVID-19-Task-Force-CDER@fda.hhs.gov detailing corrective actions, including documentation and steps to prevent recurrence. Failure to comply may result in legal action, including seizure and injunction. NeuroXPF will be added to FDA's public list of firms selling fraudulent COVID-19 products.

The FTC also cited violations of the FTC Act, stating that claims of preventing, treating, or curing human disease require competent and reliable scientific evidence, which is

Company
NeuroXPF
Inspection date
March 27, 2020
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Donald D. Ashley (Director)
  • Richard A. Quaresima
View Company Profile

ID · 72261151-8e04-461c-8e5f-ebc76a0fdd74

Violation Codes4
21.U.S.C. 355(a)21 U.S.C. 35221 U.S.C. 331(d)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore NeuroXPF
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.